A pilot double-blind placebo-controlled trial of pioglitazone as adjunctive treatment to risperidone: Effects on aberrant behavior in children with autism

Content Provider	Semantic Scholar
Author	Ghaleiha, Ali Rasa, Soudeh Mohebbi Nikoo, Mohammadali Farokhnia, Mehdi Akhondzadeh, Shahin
Copyright Year	2015
Abstract	To assess the safety and efficacy of pioglitazone added to risperidone in the treatment of irritability in autistic disorder (AD), we conducted this study. In a 10-week, randomized, double-blind, parallel-group, placebo-controlled clinical trial, 44 outpatients of both genders aged 4-12 years with a diagnosis of AD and a score of ≥12 on the Aberrant Behavior Checklist-Community (ABC-C) irritability subscale were included. Mean change of ABC-C irritability subscale score as primary outcome, change in other ABC-C subscale scores and partial and complete responses were compared between two groups. Twenty patients completed the trial in each group. Level of reduction and effect of time×treatment interaction in the treatment group were significant for irritability (P=0.03), lethargy/social withdrawal (P=0.04) and hyperactivity/non-compliance (P=0.03) but not for stereotypic behavior and inappropriate speech subscales compared with the placebo group. Vomiting and headache were the most frequent reported side-effects. Results of this preliminary study indicate positive effects of pioglitazone compared with placebo in improving the behavioral symptoms of AD.
Starting Page	181
Ending Page	187
Page Count	7
File Format	PDF HTM / HTML
DOI	10.1016/j.psychres.2015.07.043
Alternate Webpage(s)	https://api.elsevier.com/content/article/pii/S0165178115005004
Alternate Webpage(s)	https://www.sciencedirect.com/science/article/pii/S0165178115005004?dgcid=api_sd_search-api-endpoint
PubMed reference number	26208985
Alternate Webpage(s)	https://doi.org/10.1016/j.psychres.2015.07.043
Journal	Medline
Volume Number	229
Journal	Psychiatry Research
Language	English
Access Restriction	Open
Content Type	Text
Resource Type	Article